SCHEMBL2237995

SCHEMBL2237995

CCOC(=O)NN(C(=O)Oc1ccccc1)c1ccccc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
MAPT P10636 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2236089 0.91 ALDH1A1 (0.43) HPGDMAPTNPSR1TSHRHSD17B10
SCHEMBL2235392 0.89 POLB (0.41) RAB9AMAPTKDM4ESMN1; SMN2GAA
SCHEMBL2234563 0.89 KDM4E (0.43) HPGDRAB9ANPC1MAPTNPSR1
SCHEMBL2232497 0.82 MAPT (0.41) HPGDRAB9ANPC1MAPTNPSR1
SCHEMBL2236717 0.82 ALDH1A1 (0.53) HPGDRAB9ANPC1CRHBPCRHR2
SCHEMBL2236294 0.79 ATM (0.47) HPGDNPC1MAPTNPSR1SMN1; SMN2
SCHEMBL2232860 0.79 ATM (0.44) MAPTHSD17B10SMN1; SMN2MTNR1BALDH1A1
SCHEMBL2233414 0.76 LIPE (0.53) RAB9AMAPTNPSR1MEN1KMT2A
SCHEMBL2233778 0.76 FAAH (0.49) HPGDRAB9ANPC1MAPTNPSR1
SCHEMBL2233290 0.75 ALDH1A1 (0.50) MAPTSMN1; SMN2GAALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299264-B2 Method for producing oxadiazolinone compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-30 US disclosed
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-25 US disclosed
EP-2357167-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2011-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF AHR, CYP1B1, AR HPGD 450/4885RAB9A 2781/4885NPC1 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.